Clinical Trials Logo

Filter by:
NCT ID: NCT06113328 Recruiting - Clinical trials for Non-segmental Vitiligo

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Start date: November 27, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of MK-6194 in participants with non-segmental vitiligo. The primary hypothesis is that at least 1 MK-6194 dose is superior to placebo with regards to percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24.

NCT ID: NCT06112743 Recruiting - Clinical trials for Cardiomyopathy, Hypertrophic

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

MEMENTO
Start date: January 24, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) [New York Heart Association (NYHA) Functional Class II or III].

NCT ID: NCT06112379 Recruiting - Breast Cancer Clinical Trials

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Start date: November 14, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

NCT ID: NCT06112314 Recruiting - Advanced Melanoma Clinical Trials

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

PRISM-MEL-301
Start date: December 18, 2023
Phase: Phase 3
Study type: Interventional

This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

NCT ID: NCT06112236 Active, not recruiting - Hypophosphatemia Clinical Trials

Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

Start date: February 17, 2023
Phase:
Study type: Observational

The aim of this study is to generate evidence regarding hypophosphatemia after iron infusion in lung transplant recipients in context of anemia and/or iron deficiency.

NCT ID: NCT06111898 Recruiting - Cerebral Palsy Clinical Trials

Neuro-biomechanical Determinants for Motor Behavior in High-risk Infants

BAMBI
Start date: October 10, 2023
Phase:
Study type: Observational

This project focuses on motor development, muscle growth and muscle activity. Using advanced, instrumented tests such as , the link between muscles and the movement characteristics will be studied. In addition, the evolution of these neuro-biomechanical determinants during the first year of life will be investigated. The examinations are planned for a group of high-risk infants (e.g. premature birth, cases of asphyxia, etc.) compared with a group of infants with typical development.

NCT ID: NCT06111885 Not yet recruiting - Kidney Stone Clinical Trials

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

INDAPACHLOR
Start date: April 2024
Phase: Phase 2
Study type: Interventional

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

NCT ID: NCT06108648 Recruiting - Bronchiolitis Clinical Trials

Efficacy of Lavender Essential Oil Chest Wraps in Infants With Bronchiolitis

Start date: December 7, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn if lavender essential oil chest wraps relieve cough in infants with bronchiolitis compared to standard care. Furthermore, the researchers will evaluate if breathing difficulties, nighttime awakening and impact on parents will be improved by the lavender oil chest wraps. Infants will be randomized to receive standard care with the addition of lavender oil chest wraps or to receive standard care alone. The study will take place in two locations in Switzerland, at the Geneva University Hospital and the Fribourg Cantonal Hospital.

NCT ID: NCT06108375 Recruiting - Terminal Illness Clinical Trials

Differences in Acceptability of Music Therapy Sessions Played Live Compared to a Recording Thereof

Start date: October 24, 2023
Phase: N/A
Study type: Interventional

The present study seeks to assess differences in feasibility and acceptability of music therapy played live and listening to a recording thereof at the palliative care ward of the University Hospital Zurich. As a secondary objective the investigators aim to extend the limited findings on the putative effect of music therapy in palliative care populations derived from objective measures of human autonomic response combined with subjective psychological outcomes to support evidence-based medicine. The investigators will implement a commercially available tracker, the wristband 287-2 by Corsano, to investigate multiple simultaneous biomarkers of autonomic response to music therapy and a recording thereof, such as heart rate, heart rate variability, electrodermal activity and distal body temperature. To investigate subjective quality of life and psychological outcomes, the investigators will administer highly validated and widely used questionnaires, namely the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 15 Palliative Care, the Edmonton Symptom Assessment System and the Hospital Anxiety and Depression Scale.

NCT ID: NCT06108258 Completed - Clinical trials for Iron Induced Hypophosphatemia

Newborn Phosphocalcic Metabolism After Intravenous Iron Administration During Pregnancy

Start date: September 23, 2022
Phase:
Study type: Observational

Iron deficiency anemia (IDA) is a very common health problem during pregnancy and intravenous (IV) iron substitution has become part of routine management. Recent studies have raised concerns about association of IV iron infusion and development of secondary transitory hypophosphatemia (HP) in adults including pregnant women. The study aimed to evaluate the impact of IV iron administration during pregnancy on newborn's phosphatemia. The investigators conducted a prospective, single-center, observational study in the Geneva University Hospitals (HUG), from September 2022 to March 2023. Pregnant women treated either with IV iron or with oral iron during pregnancy were included. At delivery, a maternal blood sample to assess hemoglobin, hematocrit, ferritin, phosphate and calcium and an umbilical cord blood sample to assess levels of phosphate and calcium were collected. Difference in demographics and clinical characteristics between the two groups were explored using univariate analyses. Multivariate analyses were performed to test the contribution of IV iron substitution on cord blood phosphatemia and calcemia, considering potential confounding factors. Neonatal HP was defined as a phosphate level lower than 1.3 mmol/L.